Including debt, the deal, which is expected to close in the third quarter of this year, is valued around $5.2 billion.
Although Anacor currently doesn’t have any products on the market, it has the rights to Kerydin, a treatment for toenail fungus, according to the report. Pfizer believes Kerydin and Anacor’s other offerings would balance Pfizer’s inflammation and immunology products.
More articles on transaction and valuation issues:
Texas Health Resources casts highest bid for bankrupt Fort Worth hospital
Following collapse of Novant, Memorial partnership, HCA enters with offer
HCA to buy yet-to-open Texas hospital for $115M
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
